Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00001373 |
Recruitment Status :
Recruiting
First Posted : November 4, 1999
Last Update Posted : April 26, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases.
The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 7 years of age or older.
Patients will undergo a medical and family history, physical examination, blood and urine tests. Additional tests and procedures may include the following:
- X-rays
- Consultations with specialists
- DNA sample collection (blood or saliva sample) for genetic studies. These might include studies of specific genes, or more complete sequencing of the genome.
- Additional blood samples a maximum of 1 pint (450 ml) during a 6-week period for studies of white cell adhesion (stickiness)
- Leukapheresis for collecting larger amounts of white cells for study. For this procedure, whole blood is collected through a needle in an arm vein. The blood flows through a machine that separates it into its components. The white cells are removed and the rest of the blood is returned to the body through another needle in the other arm.
Patients may be followed approximately every 6 months to monitor symptoms, adjust medicine dosages, and undergo routine blood and urine tests. They will receive genetic counseling by the study team on the risk of having affected children and be advised of treatment options.
Participating relatives will undergo a medical and family history, possibly with a review of medical records, physical examination, blood and urine tests. Additional procedures may include a 24-hour urine collection, X-rays, and consultations with medical specialists. A DNA sample (blood or saliva) will also be collected for genetic studies. Additional blood samples of no more than 550 mL during an 8-week period may be requested for studies of white cell adhesion (stickiness).
Relatives who have familial Mediterranean fever, TRAPS, or hyper-IgD syndrome will receive the same follow-up and counseling as described for patients above.
Normal volunteers and patients with gout will have a brief health interview and check of vital signs (blood pressure and pulse) and will provide a blood sample (up to 90 ml, or 6 tablespoons). Additional blood samples of no more than 1 pint over a 6-week period may be requested in the future.
Condition or disease |
---|
Familial Mediterranean Fever (FMF) Autoinflammation Periodic Fever Fever Genetic Diseases ROSAH ALPK1 |
Study Type : | Observational |
Estimated Enrollment : | 5000 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | An Exploratory Study of the Genetics, Pathophysiology, and Natural History of Autoinflammatory Diseases |
Actual Study Start Date : | March 10, 1994 |
Group/Cohort |
---|
Affected
Patients with auto-inflammatory disorders
|
Family Members
Family members of patients
|
Healthy Volunteers
Healthy Volunteers
|
- Genetic linkage in autoinflammatory dise [ Time Frame: annually ]discovery of genetic associations to autoinflammatory disorders
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 2 Months to 115 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
- INCLUSION CRITERIA:
There are three populations that will be included in this study: subjects with known or suspected autoinflammatory diseases, family members of subjects with known or suspected autoinflammatory diseases, and healthy controls. In order to be eligible to participate in this study as a subject with known or suspected autoinflammatory disease, an individual must meet all of the following criteria:
- Stated willingness to participate in study procedures (which at the very least includes providing a mail-in sample for genetic analysis);
- Regardless of gender, at least one month of age;
- A medical history that, in the expert opinion of the study team, is consistent with the possibility of autoinflammatory disease; and
- Ability of the subject, parents (in the case of children), or Legally Authorized Representative to understand and the willingness to sign a written informed consent document.
In order to be eligible to participate in this study as a family member of a subject with known or suspected autoinflammatory disease, an individual must meet all of the following criteria:
- Stated willingness to participate in study procedures (which at the very least includes providing a mail-in sample for genetic analysis);
- Regardless of gender, at least one month of age;
- Relationship, either by blood or marriage, to an individual enrolled or about to be enrolled in the study with known or suspected autoinflammatory disease;
- Likelihood, in the expert opinion of the study team, that analysis of a sample from the individual would advance genetic or functional analysis of the affected relative s possible autoinflammatory condition; and
- Ability of the subject, parents (in the case of children), or Legally Authorized Representative to understand and the willingness to sign a written informed consent document.
In order to be eligible to participate in this study as a healthy volunteer, an individual must meet all of the following criteria:
- Stated willingness to participate in study procedures for healthy volunteers;
- Regardless of gender, at least one year old, and not pregnant (by history of a missed menstrual period);
- Likelihood, in the expert opinion of the study team, that a sample from the individual would advance the functional analysis of an autoinflammatory condition under study; and
- Ability of the subject or parents (in the case of children) to understand and the willingness to sign a written informed consent document.
EXCLUSION CRITERIA:
For any of the three categories of subjects, an individual will be excluded from participation in this study if he or she has a medical condition that would, in the opinion of the investigators, confuse the interpretation of the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001373
Contact: Amanda K Ombrello, M.D. | (301) 827-4258 | ombrelloak@mail.nih.gov | |
Contact: Daniel L Kastner, M.D. | (301) 496-8364 | kastnerd@mail.nih.gov |
United States, District of Columbia | |
Childrens National Medical Center | Completed |
Washington, District of Columbia, United States, 20010 | |
United States, Maryland | |
Johns Hopkins University | Completed |
Baltimore, Maryland, United States, 21205 | |
Walter Reed National Medical Center | Completed |
Bethesda, Maryland, United States, 20301 | |
National Institutes of Health Clinical Center | Recruiting |
Bethesda, Maryland, United States, 20892 | |
Contact: NIH Clinical Center Office of Patient Recruitment (OPR) 800-411-1222 ext TTY dial 711 ccopr@nih.gov | |
United States, Pennsylvania | |
University of Pittsburgh | Not yet recruiting |
Pittsburgh, Pennsylvania, United States, 15261 | |
Contact: Daniella Schwartz 412-648-1587 Daniella.Schwartz@pitt.edu |
Principal Investigator: | Daniel L Kastner, M.D. | National Human Genome Research Institute (NHGRI) |
Publications:
Responsible Party: | National Human Genome Research Institute (NHGRI) |
ClinicalTrials.gov Identifier: | NCT00001373 |
Other Study ID Numbers: |
940105 94-HG-0105 |
First Posted: | November 4, 1999 Key Record Dates |
Last Update Posted: | April 26, 2024 |
Last Verified: | March 26, 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | .Individual genomic sequencing data and corresponding phenotype data will be deposited in dbGaP as part of the study's Genomic Data Sharing Plan. Non-genomic and/or phenotypic individual data will not be deposited in shared databases for broad research use. |
Supporting Materials: |
Study Protocol Analytic Code |
Time Frame: | Genomic Sharing Plan in effect since 2018 with genomic data deposited to dbGaP for broad availability within six months of final data analysis of each genomic sequence. No end date of data availability through dbGaP. |
Access Criteria: | Genomic sequences will be deposited to dbGaP following final sequence analysis and available for broad use, as determined by dbGaP usage committee. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Splenomegaly Retinal Dystrophy Periodic Fever Optic Nerve Edema HEADACHE |
Genetics Familial Mediterranean Autoinflammation Anhidrosis Alpha-Kinase 1 |
Hereditary Autoinflammatory Diseases Brucellosis Genetic Diseases, Inborn Familial Mediterranean Fever Fever Hyperthermia Body Temperature Changes Heat Stress Disorders |
Wounds and Injuries Gram-Negative Bacterial Infections Bacterial Infections Bacterial Infections and Mycoses Infections Skin Diseases, Genetic Skin Diseases |